604-50-2

Basic information

• Product Name: 1-methylquinazoline-2,4(1H,3H)-dione
• Synonyms: 1-methylquinazoline-2,4(1H,3H)-dione;1-Methyl-1,2,3,4-tetrahydroquinazoline-2,4-dione;1-Methyl-2,4(1H,3H)-quinazolinedione;1-Methyl-5,6-[1,3]butadienopyrimidine-2,4(1H,3H)-dione;Glycosmicine;1-methyl-2,4(1H,3H)-quinazolinedione(SALTDATA: FREE);1-methylquinazoline-2,4-dione;1-methylquinazoline-2,4-quinone
• CAS NO: 604-50-2
• Molecular Formula: C₉H₈N₂O₂
• Molecular Weight: 176.18
• Mol File: 604-50-2.mol
• Article Data: 17

Chemical Properties

• Appearance: /
• Density: 1.292 g/cm³
• Refractive Index: 1.585
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 1-methylquinazoline-2,4(1H,3H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 1-methylquinazoline-2,4(1H,3H)-dione(604-50-2)
• EPA Substance Registry System: 1-methylquinazoline-2,4(1H,3H)-dione(604-50-2)

Safety Data

• Hazardous Substances Data: 604-50-2(Hazardous Substances Data)

Usage

General Description

1-methylquinazoline-2,4(1H,3H)-dione is a heterocyclic organic compound with a quinazoline backbone and a methyl substituent at the 1-position. It is a derivative of quinazoline and is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. This chemical compound has been studied for its potential in medicinal chemistry, particularly as a scaffold for developing drugs targeting various diseases. Its molecular structure and reactivity make it a valuable intermediate in the synthesis of various biologically active compounds. Additionally, 1-methylquinazoline-2,4(1H,3H)-dione has also been investigated for its potential applications in materials science, such as in the development of organic electronic and optoelectronic devices.

InChI:InChI=1/C9H8N2O2/c1-11-7-5-3-2-4-6(7)8(12)10-9(11)13/h2-5H,1H3,(H,10,12,13)

Upstream product

• 7505-81-9 2-methylaminobenzamide 
• 57-13-6 urea 
• 119-68-6 N-Methylanthranilic acid 
• 77-78-1 dimethyl sulfate 
• 10328-92-4 N-Methylisatoic anhydride 
• 917-61-3 sodium isocyanate 
• 590-28-3 potassium cyanate 
• 85-91-6 Methyl N-methylanthranilate 
• 134-20-3 2-carbomethoxyaniline 
• 7664-93-9 sulfuric acid 
• 86-96-4 1,2,3,4-tetrahydro-quinazoline-2,4-dione 
• 74-88-4 methyl iodide 
• 541-41-3 chloroformic acid ethyl ester 

Downstream Products

• 1436384-11-0 3-(3-(2-hydroxyphenylamino)propanoyl)-1-methylquinazoline-2,4(1H,3H)-dione 
• 1436384-12-1 3-(3-(3-hydroxyphenylamino)propanoyl)-1-methylquinazoline-2,4(1H,3H)-dione 
• 1436384-13-2 3-(3-(4-hydroxyphenylamino)propanoyl)-1-methylquinazoline-2,4(1H,3H)-dione 
• 1436384-14-3 3-(3-((2-hydroxy-5-nitrophenyl)amino)propanoyl)-1-methylquinazoline-2,4(1H,3H)-dione 
• 1436384-15-4 3-(3-((4-methoxy-2-nitrophenyl)amino)propanoyl)-1-methylquinazoline-2,4(1H,3H)-dione 
• 1436384-16-5 3-(3-((4-aminophenyl)amino)propanoyl)-1-methylquinazoline-2,4(1H,3H)-dione 
• 1436384-17-6 3-(3-((3-bromo-4-methylphenyl)amino)propanoyl)-1-methylquinazoline-2,4(1H,3H)-dione 
• 1436384-18-7 3-(3-((3-chlorophenyl)amino)propanoyl)-1-methylquinazoline-2,4(1H,3H)-dione 
• 1436384-19-8 3-(3-((4-chlorophenyl)amino)propanoyl)-1-methylquinazoline-2,4(1H,3H)-dione 
• 1400799-32-7 N-(2-chlorobenzoyl)glycine-2-(1,4-dihydro-1-methyl-2,4-dioxo-3(2H)-quinazolinyl)ethyl ester 
• 1400799-33-8 N-(2-methylbenzoyl)glycine-2-(1,4-dihydro-1-methyl-2,4-dioxo-3(2H)-quinazolinyl)ethyl ester 
• 1400799-34-9 N-(4-nitrobenzoyl)glycine-2-(1,4-dihydro-1-methyl-2,4-dioxo-3(2H)-quinazolinyl)ethyl ester 
• 1400799-37-2 N-(4-methoxybenzoyl)glycine-2-(1,4-dihydro-1-methyl-2,4-dioxo-3(2H)-quinazolinyl)ethyl ester 
• 1400799-38-3 N-(4-methylbenzoyl)glycine-2-(1,4-dihydro-1-methyl-2,4-dioxo-3(2H)-quinazolinyl)ethyl ester 

Relevant articles and documents

Quinazolines. 2*. unsymmetric 1,3-dialkyl-6-chlorosulfonyl- quinazoline-2,4-diones in nucleo- philic substitution reactions

The corresponding 6-chlorosulfonylquinazoline-2,4-diones were synthesized by the reactions of 1-methylquinazoline-2,4-dione and its 3-alkyl-substituted derivatives with chlorosulfonic acid. Treatment of the products with nucleophilic agents (water or ammo

Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides

DNA damage repair enzymes are promising targets in the development of new therapeutic agents for a wide range of cancers and potentially other diseases. The enzyme poly(ADP-ribose) glycohydrolase (PARG) plays a pivotal role in the regulation of DNA repair mechanisms; however, the lack of potent drug-like inhibitors for use in cellular and in vivo models has limited the investigation of its potential as a novel therapeutic target. Using the crystal structure of human PARG in complex with the weakly active and cytotoxic anthraquinone 8a, novel quinazolinedione sulfonamides PARG inhibitors have been identified by means of structure-based virtual screening and library design. 1-Oxetan-3-ylmethyl derivatives 33d and 35d were selected for preliminary investigations in vivo. X-ray crystal structures help rationalize the observed structure-activity relationships of these novel inhibitors.

2-QUINOLONE DERIVED INHIBITORS OF BCL6

The present invention relates to compounds of formula I that function as inhibitors of BCL6(B- cell lymphoma 6) activity: Formula I wherein X1, X2, X3, R1, R2, R3, R4 and R5 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer,as well as other diseases or conditions in which BCL6 activity is implicated.

2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG

The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.